|
UCLA study finds brain response differences in the way women with IBS anticipate and react to pain
January 09, 2008Findings may lead to new understanding of disorder and novel treatment approaches
UCLA researchers found that women with IBS cannot effectively turn-off a pain modulation mechanism in the brain, which causes them to be more sensitive to abdominal pain, compared to women without IBS.
The findings, appearing in the January 9 issue of the Journal of Neuroscience, may lead to a greater understanding of irritable bowel syndrome and new treatment approaches.
Irritable bowel syndrome affects 10 to 15 percent of the U.S. population and causes discomfort in the abdomen, along with diarrhea and/or constipation. Currently there is no cure and treatments only lessen symptoms.
"A large number of patients with irritable bowel disease suffer major decrements in their quality of life," said Dr. Emeran Mayer, study author and professor of medicine, digestive diseases and physiology, David Geffen School of Medicine at UCLA.. "Our research team studies the brain activity underlying the pain experience in patients with chronic pain disorders like IBS."
Previous research in the field has shown that the brain can prepare for pain in ways that either inhibit or amplify the sensory experience. When expected pain is predictable, tolerable, inescapable and will result in a reward -- like a doctor's injection to improve your health -- most people tell their brain to inhibit the intensity of the pain experience. One way they do this is by turning down the gain within brain circuits that process the pain signal --- similar to turning down the volume on a stereo amplifier -- in order to make the body's perception of pain less acute.
When anticipated pain is perceived as escapable and potentially dangerous - such as burning your hand on a hot stove - most people tell their brain to amplify the pain response, which is like increasing the volume on a stereo amplifier, in order to react faster and minimize possible tissue damage.
The current study showed that IBS patients cannot turn down the amplifier of the pain response, even when expected pain is not dangerous, which makes them more sensitive to even mild discomfort.
UCLA researchers used functional magnetic resonance imaging (fMRI) to record brain activity of 14 women with IBS and 12 healthy women during cued anticipation and mild abdominal pain stimulus.
During anticipation of pain, subjects without IBS decreased activity within brain areas involved with pain and emotional arousal, including the insula, amygdala and brainstem. IBS patients could not deactivate these circuits effectively, although they also knew the pain was not dangerous.
"The abdominal hypersensitivity that is a hallmark of IBS may represent an inability to downregulate pain and emotional arousal circuits, said Steven Berman, lead study author and a senior research scientist at UCLA. "IBS patients may have an inability to inhibit the competing tendency to upregulate emotional arousal in order to escape pain faster."
As expected, IBS patients reported lower pain thresholds and more anxiety than healthy women. Anxiety correlated with more brain activity during anticipation, but not receipt of pain.
"Negative emotions like anxiety and anger may interfere with the brain's ability to strategically downregulate pain arousal pathways, in situations where such an increased sensitivity is maladaptive," said Berman.
Both groups of women increased activity in pain arousal areas during receipt of pain, but IBS patients showed greater boosts in several brain structures. The lower degree of anticipatory inhibition was associated with more activity during pain in executive cortical areas of the brain, which are associated with pain coping.
"We found that the lower the brain response during anticipation in the arousal circuits, the less the dampening effect of the cortex on pain sensitivity during the actual pain stimulus," said Berman.
Researchers note that explaining this phenomenon in IBS leads to the classic chicken and egg debate: How much of the anticipatory brain dysfunction was produced by the long history of abdominal pain in patients, and how much did it predate and cause their symptoms"
"Additional research may reveal that some pain patients have a primary difference in their brain's reaction to pain," said Mayer, director of the UCLA Center for the Neurobiology of Stress. "If we can identify receptors and genes associated with these abnormal brain responses, we should improve both identification of predisposed patients and development of effective remedies."
Several converging findings from UCLA and other research groups support the importance of this research for better understanding IBS and other functional pain syndromes, such as fibromyalgia. Female patients show greater abnormalities than their male counterparts in this early brain response, and genetic factors have been identified which may predispose to an altered responsiveness of emotional arousal circuits.
University of California - Los Angeles
Irritable bowel syndrome affects 10 to 15 percent of the U.S. population and causes discomfort in the abdomen, along with diarrhea and/or constipation. Currently there is no cure and treatments only lessen symptoms.
"A large number of patients with irritable bowel disease suffer major decrements in their quality of life," said Dr. Emeran Mayer, study author and professor of medicine, digestive diseases and physiology, David Geffen School of Medicine at UCLA.. "Our research team studies the brain activity underlying the pain experience in patients with chronic pain disorders like IBS."
Previous research in the field has shown that the brain can prepare for pain in ways that either inhibit or amplify the sensory experience. When expected pain is predictable, tolerable, inescapable and will result in a reward -- like a doctor's injection to improve your health -- most people tell their brain to inhibit the intensity of the pain experience. One way they do this is by turning down the gain within brain circuits that process the pain signal --- similar to turning down the volume on a stereo amplifier -- in order to make the body's perception of pain less acute.
When anticipated pain is perceived as escapable and potentially dangerous - such as burning your hand on a hot stove - most people tell their brain to amplify the pain response, which is like increasing the volume on a stereo amplifier, in order to react faster and minimize possible tissue damage.
The current study showed that IBS patients cannot turn down the amplifier of the pain response, even when expected pain is not dangerous, which makes them more sensitive to even mild discomfort.
UCLA researchers used functional magnetic resonance imaging (fMRI) to record brain activity of 14 women with IBS and 12 healthy women during cued anticipation and mild abdominal pain stimulus.
During anticipation of pain, subjects without IBS decreased activity within brain areas involved with pain and emotional arousal, including the insula, amygdala and brainstem. IBS patients could not deactivate these circuits effectively, although they also knew the pain was not dangerous.
"The abdominal hypersensitivity that is a hallmark of IBS may represent an inability to downregulate pain and emotional arousal circuits, said Steven Berman, lead study author and a senior research scientist at UCLA. "IBS patients may have an inability to inhibit the competing tendency to upregulate emotional arousal in order to escape pain faster."
As expected, IBS patients reported lower pain thresholds and more anxiety than healthy women. Anxiety correlated with more brain activity during anticipation, but not receipt of pain.
"Negative emotions like anxiety and anger may interfere with the brain's ability to strategically downregulate pain arousal pathways, in situations where such an increased sensitivity is maladaptive," said Berman.
Both groups of women increased activity in pain arousal areas during receipt of pain, but IBS patients showed greater boosts in several brain structures. The lower degree of anticipatory inhibition was associated with more activity during pain in executive cortical areas of the brain, which are associated with pain coping.
"We found that the lower the brain response during anticipation in the arousal circuits, the less the dampening effect of the cortex on pain sensitivity during the actual pain stimulus," said Berman.
Researchers note that explaining this phenomenon in IBS leads to the classic chicken and egg debate: How much of the anticipatory brain dysfunction was produced by the long history of abdominal pain in patients, and how much did it predate and cause their symptoms"
"Additional research may reveal that some pain patients have a primary difference in their brain's reaction to pain," said Mayer, director of the UCLA Center for the Neurobiology of Stress. "If we can identify receptors and genes associated with these abnormal brain responses, we should improve both identification of predisposed patients and development of effective remedies."
Several converging findings from UCLA and other research groups support the importance of this research for better understanding IBS and other functional pain syndromes, such as fibromyalgia. Female patients show greater abnormalities than their male counterparts in this early brain response, and genetic factors have been identified which may predispose to an altered responsiveness of emotional arousal circuits.
University of California - Los Angeles
Abdominal Pain News and Current Abdominal Pain Events RSSStudy Underway to Find an Alternative Cure for Crohn's Disease and Ulcerative Colitis
Two research studies evaluating dietary changes and complementary medicine for the treatment of inflammatory bowel diseases (IBD) have been launched at Rush University Medical Center.
Common bowel problem linked to chili pepper pain receptor
People with irritable bowel syndrome have a higher than usual number of chilli pepper pain receptors, according to a new study published tomorrow (Wednesday 11 June).
Advances in C. difficile research
New research into the toxins, virulence, spread and prevention of the superbug Clostridium difficile is reported in the June special issue of the Journal of Medical Microbiology. These findings will play a crucial role in providing us with ammunition in the fight against a sometimes deadly pathogen.
Drug brings relief for many IBS patients who experience constipation
Many patients may soon find relief from the bloating, cramping, abdominal pain and constipation associated with irritable bowel syndrome, or IBS.
Report raises C. diff concerns; yeast-based probiotic shown to help significantly reduce recurrence
C. diff-associated disease (CDAD), otherwise known as severe intestinal disease brought on by the Clostridium difficile (C. diff) pathogen, has been the subject of heightened concern in the medical community.
MIT-led teams unravel heparin death mystery
An international team of researchers led by MIT has explained how contaminated batches of the blood-thinner heparin were able to slip past traditional safety screens and kill dozens of patients recently in the United States and Germany.
UT Southwestern surgeons complete North Texas' first single-incision gallbladder removal
UT Southwestern Medical Center surgeons have removed a gallbladder through a unique operation requiring only a single incision in the bellybutton rather than the traditional four incisions in the abdomen. It is the first such operation in North Texas.
May inflammatory bowel disease mimic gynecological disorders in its clinical presentation
Endometriosis is a condition of unknown etiology in which endometrial tissue occurs at extra-uterine sites, including ovaries, fallopian tubes, and gastrointestinal tract.
Safer and more effective way to treat Crohn's disease
An international research study, published in The Lancet, has thrown into question the current method of treating Crohn's disease - opening the door to a safer and more effective treatment option for sufferers of the chronic disease.
New findings show Enbrel significantly reduced levels of C-reactive protein
Amgen (NASDAQ: AMGN) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), today announced findings from a retrospective analysis, which demonstrated that ENBREL reduced C-reactive protein (CRP), a marker of inflammation, in patients with moderate to severe plaque psoriasis following 12 weeks of treatment.
More Abdominal Pain News Articles
| © 2008 BrightSurf.com |